Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Rhus toxicodendron is a homeopathic medicine derived from the fresh leaves of the poison ivy plant (*Toxicodendron radicans*). It is a cornerstone of homeopathic materia medica, primarily utilized for the treatment of musculoskeletal conditions such as rheumatoid arthritis, osteoarthritis, and sprains, as well as skin conditions like shingles and eczema. The preparation involves serial dilution and succussion according to homeopathic pharmacopoeia standards, typically to potencies such as 30C or 200C, where the original plant molecules are virtually absent. Clinical research, including studies sponsored by the Healthcare Homoeo Charitable Society, has evaluated its safety and efficacy in reducing joint pain and inflammation in patients with rheumatoid arthritis. While its mechanism is not defined by conventional molecular pharmacology, it is traditionally indicated for symptoms that are aggravated by initial movement or cold, damp weather but improved by continued motion.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on rhus toxicodendron.